Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth

Journal of Cell Biology

Volumn 152, Issue 4, 2001, Pages 741-751

  Webb, Donna J ^a   Thomas, Keena S ^a   Gonias, Steven L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Extracellular signal regulated kinase; Plasminogen activator inhibitor 1; Urokinase receptor; Urokinase type plasminogen activator; VLDL receptor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BETA3 INTEGRIN; MITOGEN ACTIVATED PROTEIN KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

ARTICLE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADAPTOR PROTEINS, VESICULAR TRANSPORT; BREAST NEOPLASMS; CELL DIVISION; CELL MOVEMENT; DRUG INTERACTIONS; FEMALE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, LDL; SIGNAL TRANSDUCTION; SON OF SEVENLESS PROTEINS; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

MINK CELL FOCUS-FORMING VIRUS;

EID: 0035911155     PISSN: 00219525     EISSN: None     Source Type: Journal    
DOI: 10.1083/jcb.152.4.741     Document Type: Article

References (72)

1. The very low density lipoprotein receptor mediates the cellular catabolism of lipoprotein lipase and urokinase-plasminogen activator inhibitor type I complexes
2. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
3. The 39-kDa receptor associated protein regulates ligand binding by the very low density lipoprotein receptor
4. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the uPA-u-PAR-PAI-1 system
5. Induction of cell migration by pro-urokinase binding to its receptor: Possible mechanism for signal transduction in human epithelial cells
6. Physiological consequences of loss of plasminogen activator gene function in mice
7. Role of urokinase receptor and caveolin in regulation of integrin signaling
8. Nuclear localization and regulation of ERK- and RSK-encoded protein kinases
9. Alpha-2 macroglobulin receptor/LDL receptor-related protein (LRP)-dependent internalization of the urokinase receptor
10. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression
11. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor
12. Reelin is a ligand for lipoprotein receptors
13. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?
14. The Jak/Stat pathway and urokinase receptor signaling in human aortic vascular smooth muscle cells
15. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin
16. 3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
17. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors
18. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
19. Active ERK/MAP kinase is targeted to newly forming cell-matrix adhesions by integrin engagement and v-Src
20. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling
21. Serum-induced translocation of mitogen-activated protein kinase to the cell surface ruffling membrane and the nucleus
22. The urokinase receptor is required for human monocyte chemotaxis in vitro
23. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans
24. Vitronectin - A major cell attachment-promoting protein in fetal bovine serum
25. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex
26. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure
27. Direct binding of reelin to VLDL receptor and apoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation
28. Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry
29. Clinical relevance of the urokinase-type and tissue-type plasminogen activators and of their type 1 inhibitor in breast cancer
30. Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers
31. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells
32. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders
33. Specificity of serine proteinase/serpin complex binding to very-low-density lipoprotein receptor and alpha2-macroglobulin receptor/low-density-lipoprotein-receptor-related protein
34. An emerging family of dual specificity MAP kinase phosphatases
35. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
36. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activator
37. Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
38. Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction
39. Urokinase receptor is associated with the components of the JAK1/STAT1 signaling pathway and leads to activation of this pathway upon receptor clustering in the human kidney epithelial tumor cell line TCL-598
40. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy
41. ras activation
42. Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptorin HT 1080 sarcoma cells
43. mapkk) in fibroblasts
44. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes
45. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells
46. Breast carcinoma epithelial cells express a very low-density lipoprotein receptor variant lacking the O-linked glycosylation domain encoded by exon 16, but with full binding activity for serine proteinase/serpin complexes and Mr-40,000 receptor-associated protein
47. mapk (ERK1) by growth factors: Correlation between late phase activation and mitogenicity
48. Non-enzymatic interactions between proteinases and the cell surface: Novel roles in normal and malignant cell physiology
49. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
50. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer
51. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer
52. Binding of urokinase-type plasminogen activator to its receptor in MCF-7 cells activates extracellular signal-regulated kinase 1 and 2 which is required for increased cellular motility
53. Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner
54. Urokinase-type plasminogen activator stimulates the Ras/ERK signaling pathway and MCF-7 cell migration by a mechanism that requires FAK, Src, and Shc: Rapid dissociation of Grb2/Sos-Shc complex is associated with the transient phosphorylation of ERK in urokinase-treated cells
55. Recycling of the urokinase receptor upon internalization of the uPA: Serpin complexes
56. Proteolytic cleavage of the urokinase receptor substitutes for the antagonist-induced chemotactic effect
57. Association of mitogen-activated protein kinase with the microtubule cytoskeleton
58. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: Prognostic relevance and target for therapy
59. Stimulation of DNA synthesis and cell proliferation of human mammary myoepithelial-like cells by hepatocyte growth factor/scatter factor depends on heparan sulfate proteoglycans and sustained phosphorylation of mitogen-activated protein kinases p42/44
60. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals
61. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles
62. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin
63. Plasminogen activator inhibitor-1 contains a cryptic high affinity binding site for the low density lipoprotein receptor-related protein
64. The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells
65. Interaction of the cytosolic adapter proteins with neuronal apolipoprotein E receptors and the amyloid precursor protein
66. Bimodal relationship between invasion of amniotic membrane and plasminogen activator activity
67. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin
68. Non-proteolytic role for the urokinase receptor in cellular migration in vivo
69. Embryonic fibroblasts that are genetically deficient in low density lipoprotein receptor-related protein demonstrate increased activity of the urokinase receptor system and accelerated migration on vitronectin
70. The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro
71. Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion
72. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction